€3k - €10kFirst value signal
SEC SIC 1987 3845 mapped to NACE Rev. 2 26.60 in BEIJING · F4 · US. Official registry identity, filed financial evidence and a public indicative value curve on one indexed company profile.
Historical indicative ranges based on public filings. This is not an asking price or confirmation that the company is for sale.
Based on filed company accountsThe historical curve shows where this company stood. Unlock what holds back value today, what it could be in five years and which actions matter now.
Free account · private workspace
Public filings are a starting point. Accounts, owner context and method review narrow the range and make it useful for a sale, financing or transfer.
Own this company? Claim and manage the profileYou have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
The valuation for Yubo International Biotech Ltd combines official public company figures with Upswitch sector calibration. The owner can sharpen it with their own figures and context into a full, defensible valuation curve.
Express interest and ask Upswitch to discreetly sound out the owner. We review every request before making contact.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Operating as a SEC SIC 1987 3845 mapped to NACE Rev. 2 26.60, Yubo International Biotech Ltd is registered in BEIJING, F4, the United States.
Yubo International Biotech Ltd is listed in US Securities and Exchange Commission (SEC EDGAR) under registry number 0000895464. This profile consolidates official annual accounts into one indexable company dossier.
Within the American NACE 26.60 cluster, public-record data is filed annually via the national company registry.
Across the 2021-2025 window revenue has declined, moving from €1,244,373 to €12,353. EBITDA for 2025 comes in at -€1,020,115.
A public indicative value curve is available for Yubo International Biotech Ltd, based on filed company accounts. A free account unlocks the five-year outlook and concrete actions to increase value.
The most recent annual filing covers 2025 (period end 2025-12-31).
This page is refreshed whenever new regulator-filed data for Yubo International Biotech Ltd becomes available, consolidated into a single audit-grade view.
Yubo International Biotech Ltd is registered under NACE 26.60: SEC SIC 1987 3845 mapped to NACE Rev. 2 26.60. That places the business within the American cluster for this activity.
According to the company registry, Yubo International Biotech Ltd is based in BEIJING, F4, US.
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for Yubo International Biotech Ltd may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
| 202331 Dec 2023 | €604,676 | -€1,016,394 | €1,667,269 | -€1,843,703 | Open PDF |
| 202231 Dec 2022 | €104,283 | -€1,187,125 | €2,348,551 | -€565,373 | Open PDF |
| 202131 Dec 2021 | €1,244,373 | -€1,529,643 | €4,587,233 | -€131,198 | Open PDF |
The most recently filed annual accounts cover fiscal year 2025 (period end 2025-12-31), publicly available via US Securities and Exchange Commission (SEC EDGAR).
